Achieve announces presentation of investigator-led rauora trial data demonstrating significantly fewer side effects with higher quit rates for cytisinicline compared to chantix® in first head-to

Achieve announces presentation of investigator-led rauora trial data demonstrating significantly fewer side effects with higher quit rates for cytisinicline (cytisine) compared to chantix® (varenicline) in first head-to-head comparative study.achieve life sciences inc - cytisinicline u.s. phase 3 trial expected to begin in q4 2020.achieve life sciences - subjects in cytisinicline arm were 55% more likely to quit smoking at 6 months compared to subjects who received varenicline.achieve life sciences inc - significantly fewer overall adverse events were reported in cytisinicline-treated subjects.
ACHV Ratings Summary
ACHV Quant Ranking